ArticleMedicine2026
Analysis of pubertal height gain in post-menarche girls.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menarche significantly affects linear growth, and the extent of height gain after menarche remains a key clinical concern. This study aimed to analyze the relationship between menarche timing and pubertal height gain, determine the extent of height gain after menarche, and assess whether treatment is required in cases of early puberty with advanced bone age (BA). A retrospective chart review of 43 patients aged 12 to 16 years with precocious or early puberty was conducted between January and June 2022. Eight patients were excluded due to treatment with recombinant growth hormone. The remaining 35 patients were divided into 2 groups based on whether they received gonadotropin-releasing hormone (GnRH) agonists. Of the 35 patients, 27 (77.1%) were treated with GnRH agonists. The mean age at menarche was delayed (11.5 ± 1.0 vs 12.1 ± 1.7, respectively). The mean predicted adult height (PAH) before menarche was lower in the untreated than in the treated group (156.7 ± 1.8 and 160.0 ± 1.8 cm, respectively, P < .05) in the treated group. After menarche, mean PAH was 157.0 ± 0.7 cm in the untreated group and 160.5 ± 0.9 cm in the GnRH agonist group (P = .04). Height gain after menarche was greater in the untreated group, 6.6 ± 3.9 versus 4.9 ± 3.0 cm, though it was not statistically significant. Importantly, the final height increase after menarche was negatively correlated with advanced BA before menarche (r = -0.092, P < .001). The mean age at menarche was delayed in the GnRH agonist group, and the final PAH was higher than that in the untreated group. However, a later age at menarche was associated with lower pubertal height gain. An increase in PAH after treatment can be anticipated in patients with an advanced BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.